A Phase I Randomized, Double-blind, Placebo-controlled, Dose Finding Clinical Trial to Evaluate the Safety and Immunogencity of H7N9 Influenza Antigen Adjuvanted With 2 Different Adjuvant Formulations in Healthy Adult Volunteers in Brazil
Overview
- Phase
- Phase 1
- Intervention
- Not specified
- Conditions
- Influenza
- Sponsor
- Butantan Institute
- Enrollment
- 432
- Locations
- 3
- Primary Endpoint
- Number of participants with solicited local Adverse Events over the 7-day period post each study injection.
- Status
- Completed
- Last Updated
- 5 years ago
Overview
Brief Summary
The overall aim of this study is to evaluate the safety, immunogenicity and dose sparing effects of H7N9 influenza antigen formulated with 2 different adjuvants .
Detailed Description
Following the emergence of avian influenza A/H7N9 influenza virus in humans in China in March 2013, the WHO Essential Regulatory Laboratories prepared candidate vaccine viruses and reagents for further development and several manufacturers have developed various inactivated influenza vaccines with and without adjuvant against A/H7N9 and tested these candidates in trials in healthy adults. The overall aim of this study is to evaluate the safety, immunogenicity and dose sparing effects of H7N9 influenza antigen produced by Butantan Institute in combination with 2 different adjuvants.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Healthy male or female (non-pregnant) adults 18 through 59 years of age at the enrollment visit.
- •To be available to participate in the study throughout its duration (approximately seven months).
- •Healthy, as established by the medical history, physical examination, and screening laboratory evaluations.
- •Capable and willing to complete Participant Diaries and willing to return for all follow-up visits.
- •To demonstrate intention to participate in the study, as documented by signature in the study´s informed consent form.
- •For females of child-bearing potential, willing to utilize reliable birth control measures from Day 0 through at least 60 days following the last study vaccination.
Exclusion Criteria
- •Participation in another clinical trial involving any experimental therapy within the previous three months or planned enrollment in such a trial during the period of this study.
- •Evidence of active neurological, cardiac, pulmonary, hepatic or renal disease as clinical history and/or physical examination (except hypertension under control).
- •Compromised immune system diseases including: HIV, Hepattis B and C, diabetes mellitus, cancer (except basal cell carcinoma) and autoimmune diseases.
- •Behavioral, cognitive or psychiatric disease that in the opinion of the principal investigator or his representative physician, affects the participant ability to understand and cooperate with all study protocol requirements.
- •Abusive usage of alcohol or drugs in the past 12 months that has caused medical, professional or family problems, indicated by clinical history.
- •Known systemic hypersensitivity to eggs or to any component of the vaccine.
- •History of severe adverse reaction after previous administration of an Influenza vaccine within 6 weeks following vaccination.
- •History of Guillain-Barre Syndrome or other demyelinating disease.
- •Have a history of severe reactions following previous immunization with licensed or unlicensed influenza virus vaccines.
- •Diagnosis of asthma with a history of hospitalization related to this condition in the last six months due to illness.
Outcomes
Primary Outcomes
Number of participants with solicited local Adverse Events over the 7-day period post each study injection.
Time Frame: 7-day period post each study injection (Days 0-6)
Solicited local Adverse Events (AE) include erythema, swelling/induration, pain/tenderness, ecchymosis, pruritis. The participant will be given a Participant Diary, a digital thermometer and ruler in which the participant will be asked to record any local and/or systemic reactions. The participant will have been instructed that if he/she experiences an AE requiring medical care, the participant should inform the study staff as soon as possible and seek medical care as appropriate. A visit will be schedule to occur 7 days after each study injection. Study staff will review the Participant Diary and interim history with the participant and inquire about new medical events, which will be recorded in the appropriate Clinical Research Forms.
Number of participants with solicited systemic Adverse Effects over the 7-day period post each study injection.
Time Frame: 7-day period post each study injection (Days 0-6)
Solicited systemic Adverse Events (AE) include fever, fatigue/malaise, myalgia, arthralgia, chills, nausea/vomiting, and headache. The participant will be given a Participant Diary, a digital thermometer and ruler in which the participant will be asked to record any local and/or systemic reactions. The participant will have been instructed that if he/she experiences an AE requiring medical care, the participant should inform the study staff as soon as possible and seek medical care as appropriate. A visit will be schedule to occur 7 days after each study injection. Study staff will review the Participant Diary and interim history with the participant and inquire about new medical events, which will be recorded in the appropriate Clinical Research Forms.
Number of participants with unsolicited local and/or systemic Adverse Events over the 7-day period post each study injection.
Time Frame: 7-day period post each study injection (Days 0-6)
Unsolicited local and/or systemic Adverse Events include any AE not include in the description of solicited AE, as described in Outcome 1 and 2. The participant will be given a Participant Diary, a digital thermometer and ruler in which the participant will be asked to record any local and/or systemic reactions. The participant will have been instructed that if he/she experiences an AE requiring medical care, the participant should inform the study staff as soon as possible and seek medical care as appropriate. A visit will be schedule to occur 7 days after each study injection. Study staff will review the Participant Diary and interim history with the participant and inquire about new medical events, which will be recorded in the appropriate Clinical Research Forms.
Secondary Outcomes
- Number of participants with unsolicited local and/or systemic Adverse Events over the 28-day period post each study injection.(28-day period post each study injection (Days 0-27))
- Number of participants with Serious Adverse Events over the 222-day period post second study injection.(222-day period post the second study injection (Days 0-221))
- Number of participants that presented seroconversion at day 28, 45 and 56 post first study injection(56-day period post the first study injection)
- Number of participants that presented seroprotection at day 28, 45 and 56 post first study injection(56-day period post the first study injection)
- Geometric mean of Hemagglutination-inhibition titre at day 28, 45 and 56 post first study injection(56-day period post the first study injection)